• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Roche Holding Ltd (OP: RHHVF )

    299.36 -0.73 (-0.24%)
    Streaming Delayed Price Updated: 3:33 PM EST, Nov 12, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Roche Holding Ltd

    < Previous 1 2 3 4 5 6 7 Next >
    Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial
    Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (dupilumab... 
    Via Benzinga
    Roche Expects Slower FY22 Sales Growth On Lower Demand For COVID-19 Tests
    Roche Holdings AG's (OTC: RHHBY) FY21 sales increased 8% Y/Y (9% on a constant currency basis) to CH 
    Via Benzinga
    Novartis Expects FY22 Sales, Profit Growth; Sandoz Review Continues
    Novartis AG (NYSE: NVS) reported a Q4 net income of $16.31 billion, up from $2.1 billion the previous year,  
    Via Benzinga
    Biogen Exercises Option To Participate Developing Genentech's Bispecific Antibody, Mosunetuzumab
    Biogen Inc (NASDAQ: BIIB) has  
    Via Benzinga
    FDA Approves First Injectable Eye Medicine For Vision Loss Disorder - Genentech's Vabysmo
    The FDA has approved Genentech's, a unit of  
    Via Benzinga
    Genentech's Evrysdi Application Under FDA Priority Review For Use In Babies Below 2 Months
    The FDA has granted priority review for Genentech's, a unit of Roche Holdings AG (OTC: RHHBY) supplemental marketing application for Evrysdi (... 
    Via Benzinga
    CMS Proposes Coverage Of Biogen's Alzheimer's Drug, With Conditions Apply
    The Centers for Medicare & Medicaid Services (CMS) released a proposed national coverage determination for Medicare to cover drugs that target amyloid for mild... 
    Via Benzinga
    Lineage, Genentech Ink Cell Therapy Licensing Pact For Ocular Diseases
    Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into an exclusive worldwide collaboration and license agreement with Roche Holdings AG's (OTC: RHHBY)... 
    Via Benzinga
    Novartis Launches New Share Buyback Program Of Up To $15B
    Novartis AG (NYSE: NVS) is launching a new share buyback worth up to $15 billion to be executed by the end of 2023, adding it was confident in its top-line growth... 
    Via Benzinga
    After Roche Walks Away, Atea Puts Break On Late-Stage COVID-19 Oral Antiviral Trial
    Atea Pharmaceuticals Inc (NASDAQ: AVIR) said it would close the global Phase 3 MORNINGSKY trial. The decision comes after considering the changing COVID-19 landscape... 
    Via Benzinga
    Roche's Polivy Combo Boosts Survival In Early-Stage Lymphoma Patients
    Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 POLARIX study of Polivy (polatuzumab vedotin) with MabThera/Rituxan (rituximab) and the chemotherapy regimen... 
    Via Benzinga
    Roche Uncorks Favorable Responses From Mosunetuzumab In Follicular Lymphoma Settings
    Roche Holdings AG's (OTC: RHHBY) mosunetuzumab, a bispecific targeting the CD20 protein on the surface of tumors and the CD3 protein on T cells, posted a 60%... 
    Via Benzinga
    Infinity Pharma Shares Updated Eganelisib Combo Therapy In Breast Cancer Trial
    Infinity Pharmaceuticals Inc (NASDAQ: INFI) presented updated data from the ongoing MARIO-3 study during the 2021 San Antonio Breast Cancer Symposium (SABCS).... 
    Via Benzinga
    Roche Posts Encouraging Follow-up Data From Tiragolumab/Tecentriq Trial In Lung Cancer
    Roche Holdings AG (OTC: RHHBY) reported follow-up efficacy, safety, and patient-reported outcomes data from the Phase 2 CITYSCAPE trial of tiragolumab plus... 
    Via Benzinga
    Europe Approves Roche's Tocilizumab For Patients With Severe COVID-19
    The European Commission has extended the marketing authorization for Roche Holdings AG's (OTC: RHHBY) Actemra/RoActemra (Tocilizumab) to treat patients with severe... 
    Via Benzinga
    Immunocore' ImmTAC Candidate Shows Early Response In Ovarian And Head & Neck Cancer Patients
    Immunocore Holdings Plc (NASDAQ: IMCR) announced the initial Phase 1 data of IMC-C103C, a bispecific T cell engager targeting MAGE-A4, in selected advanced solid... 
    Via Benzinga
    Biden's New COVID-19 Plan Includes Reimbursement For Over The Counter, At-Home COVID Tests
    President Biden announced that private health insurance plans would soon reimburse people who buy over-the-counter (OTC), at-home rapid tests for COVID-19. What Happened... 
    Via Benzinga
    Exposures COVID-19
    Gene Therapy-Focused Dyno Therapeutics Adds Astellas To List Partner List With $1.6B Pact
    Gene therapy startup Dyno Therapeutics Inc has partnered with pharmaceutical giants such as Novartis AG (NYSE: NVS) and Roche Holdings AG (OTC: RHHBY... 
    Via Benzinga
    Roche's Gavreto Conditionally Approved In Europe For RET Fusion-Positive Lung Cancer
    The European Commission (EC) has granted conditional marketing authorization to Roche Holdings AG's (OTC: RHHBY) Gavreto (pralsetinib) for treating adults... 
    Via Benzinga
    Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?
    Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation... 
    Via Benzinga
    Spark Therapeutics' Hemophilia Gene Therapy Shows Reduction In Bleeding Episodes
    Spark Therapeutics, a unit of Roche Holdings AG (OTC: RHHBY), has announced data from its Phase 1/2 trial of SPK-8011 in hemophilia A. At a median efficacy follow-up of 33.4... 
    Via Benzinga
    Atea Shares Plunge As Roche Culls Partnership To Develop COVID-19 Pill
    Roche Holdings AG (OTC: RHHBY) has ended a partnership with Atea Pharmaceuticals Inc (NASDAQ: AVIR) to jointly develop a COVID-19 antiviral pill, a month... 
    Via Benzinga
    Exposures COVID-19
    Europe Approves Regeneron - Roche's COVID-19 Antibody Cocktail
    The European Commission (EC) has approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) COVID-19 antibody cocktail, known as REGEN-COV in the U.S. and... 
    Via Benzinga
    Exposures COVID-19
    EU Regulator Backs Regeneron-Roche's COVID-19 Drug
    The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Regeneron Pharmaceuticals Inc... 
    Via Benzinga
    Exposures COVID-19
    Hit By Slow Rollout, Biogen's Aduhelm Could Soon Find Itself In Price Competition: Reuters
    With already a snail-paced rollout of Biogen Inc's (NASDAQ: BIIB) controversial Alzheimer's treatment Aduhelm, the Company could soon face price competition.... 
    Via Benzinga
    ALX Oncology Falls After Updated Data For Solid Tumors Candidate
    ALX Oncology Holdings Inc (NASDAQ: ALXO) released additional data from a phase 1b trial of evorpacept in solid tumor malignancies. One cohort included gastric/... 
    Via Benzinga
    Regeneron-Roche's COVID-19 Treatment Shows Long Term Benefit After Single Dose
    Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has announced additional results from a Phase 3 trial, which assessed a single dose of REGEN-COV (1,200 mg... 
    Via Benzinga
    Exposures COVID-19
    Novartis To Offload Its Stake Back To Roche For $20.7B
    Novartis AG (NYSE: NVS), a shareholder in Roche Holdings AG (OTC: RHHBY) for more than 20 years, would sell its entire stake, which is nearly one-third voting... 
    Via Benzinga
    Galecto To Test GB1211 Combined with Roche's Tecentriq In First Line Lung Cancer Setting
    Galecto Inc (NASDAQ: GLTO) has entered into a clinical trial supply agreement with Roche Holdings AG (OTC: RHHBY) to explore the combination of GB1211 in... 
    Via Benzinga
    Roche Expects Higher FY21 Sales As Delta Variant Boosts Demand For Diagnostics
    Roche Holding AG (OTC: RHHBY) raised its 2021 sales forecast after posting an 8% rise in nine-month revenues, driven by demand for COVID-19 tests and the strong... 
    Via Benzinga
    Exposures COVID-19
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.